Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease

Journal of the American Society of Nephrology

Volumn 16, Issue 7, 2005, Pages 2180-2189

  Parfrey, Patrick S ^a   Foley, Robert N ^b   Wittreich, Barbara H ^c   Sullivan, Daniel J ^d   Zagari, Martin J ^c   Frei, Dieter ^c  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^c Ortho Biotech Products LP   (United States)

^d JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT;

ADULT; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIZZINESS; FEMALE; HEADACHE; HEART DILATATION; HEART DISEASE; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HEMODIALYSIS PATIENT; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; AGED; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

ADULT; AGED; ANEMIA; DOUBLE-BLIND METHOD; EPOETIN ALFA; FEMALE; HEART DISEASES; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 27144498003     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2004121039     Document Type: Article

References (35)

1. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47: 186-192, 1995
2. Acquatella H, Perez-Rojas M, Burger B, Guinand-Baldo A: Left ventricular function in terminal uremia. A hemodynamic and echocardiographic study. Nephron 22: 160-174, 1978
3. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME: Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study. J Am Soc Nephrol 12: 2759-2767, 2001
4. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE: Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 11: 1277-1285, 1996
5. Silberberg JS, Barre PE, Prichard SS, Sniderman AD: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36: 286-290, 1989
6. Stack AG, Saran R: Clinical correlates and mortality impact of left ventricular hypertrophy among new ESRD patients in the United States. Am J Kidney Dis 40: 1202-1210, 2002
7. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, Seminara G, Stancanelli B, Malatino LS; CREED Investigators: Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 12: 2768-2774, 2004
8. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28: 53-61, 1996
9. Ma JZ, Ebben J, Xia H, Collins AJ: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10: 610-619, 1999
10. Madore F, Lowrie EG, Brugnara C, Lew NL, Lazarus JM, Bridges K, Owen WF: Anemia in hemodialysis patients: Variables affecting this outcome predictor. J Am Soc Nephrol 8: 1921-1929, 1997
11. Xia H, Ebben J, Ma JZ, Collins AJ: Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 10: 1309-1316, 1999
12. Canadian Erythropoietin Study Group: Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 300: 573-578, 1990
13. McMahon LP, Johns JA, McKenzie A, Austin M, Fowler R, Dawborn JK: Haemodynamic changes and physical performance at comparative levels of haemoglobin after long-term treatment with recombinant erythropoietin. Nephrol Dial Transplant 7: 1199-1206, 1992
14. Sikole A, Polenakovic M, Spirovska V, Polenakovic B, Masin G: Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients. Artif Organs 17: 977-984, 1993
15. National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF K/DOQI): Guidelines for anemia of chronic kidney disease. Available: www.kidney.org/professionals/kdoqi/guidelines/doqiupan_ii.html. Accessed March 2, 2005
16. Churchill DN, Blake PG, Jindal KK, Toffelmire EB, Goldstein MB: Clinical practice guidelines for initiation of dialysis. Canadian Society of Nephrology. J Am Soc Nephrol 10[Suppl 13]: S289-S291, 1999
17. Locatelli F: European best practice guidelines II: Targets for anaemia treatment. Nephrol Dial Transplant 19[Suppl 2]: ii6-ii15, 2004
18. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998
19. Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, Coyle D, Fine A, Handa P, Kingma I, Lau CY, Levin A, Mendelssohn D, Muirhead N, Murphy B, Plante RK, Posen G, Wells GA: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58: 1325-1335, 2000
20. Furuland H, Linde T, Ahlmen J, Christensson A, Strombom U, Danielson BG: A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 18: 353-361, 2003
21. McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ: Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 15: 1425-1430, 2000
22. Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB: Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res 3: 329-338, 1994
23. Cella D: Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, Version 4, Evanston, Center on Outcomes, Research and Education (CORE), Evanston Northwestern Healthcare and Northwestern University, 1997
24. Fitts SS, Guthrie MR: Six-minute walk by people with chronic renal failure. Assessment of effort by perceived exertion. Am J Phys Med Rehabil 74: 54-58, 1995
25. Sahn DJ, DeMaria A, Kisslo J, Weyman A: Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 58: 1072-1083, 1978
26. Pombo JF, Troy BL, Russell RO Jr: Left ventricular volumes and ejection fraction by echocardiography. Circulation 43: 480-490, 1971
27. Devereux RB: Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization, and comparison to other methods. Hypertension 9: II9-II26, 1987
28. Lin CL, Hsu PY, Yang CT, Yang HY, Yang TY, Huang WH, Huang CC: LV mass index significantly impacts on patient and renal outcomes in patients with coronary artery bypass grafting and poor left-ventricular function. Ren Fail 25: 287-295, 2003
29. Proschan MA, Waclawiw MA: Practical guidelines for multiplicity adjustment in clinical trials. Control Clin Trials 21: 527-539, 2000
30. London GM, Zins B, Pannier B, Naret C, Berthelot JM, Jacquot C, Safar M, Drueke TB: Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int 36: 878-882, 1989
31. Macdougall IC, Lewis NP, Saunders MJ, Cochlin DL, Davies ME, Hutton RD, Fox KA, Coles GA, Williams JD: Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 335: 489-493, 1990
32. Roger SD, McMahon LP, Clarkson A, Disney A, Harris D, Hawley C, Healy H, Kerr P, Lynn K, Parnham A, Pascoe R, Voss D, Walker R, Levin A: Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): Results of a randomized clinical trial. J Am Soc Nephrol 15: 148-156, 2004
33. Leyland-Jones B: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4: 459-460, 2003
34. Hays RD, Morales LS: The RAND-36 measure of health-related quality of life. Ann Med 33: 350-357, 2001
35. Canadian Organ Replacement Register: Preliminary report for dialysis and transplantation 2002, Canadian Institute for Health Information, Ottawa, Canada 2002. Available: secure.cihi.ca/cihiweb/en/downloads/services_ corr_ e_2002prelimreport.pdf. Accessed March 2, 2005